Effect of Treatment With Biologic Agents on the Novel Inflammatory Biomarkers Systemic Immune Inflammation Index and Systemic Inflammation Response Index for Psoriasis
Keywords:
Biological agents, psoriasis, systemic immune inflammation index, systemic inflammation response index, treatmentAbstract
Introduction: Psoriasis is a chronic cutaneous disorder with underlying systemic inflammation. The systemic immune inflammation (SII) and systemic inflammation response indexes (SIRI) are novel biomarkers that indicate systemic inflammation.
Objectives: We aimed to evaluate the effect of biological agent treatment on SII and SIRI in psoriasis patients.
Methods: Between April 2019 and October 2022, SII and SIRI were retrospectively evaluated in patients with psoriasis before and three months after the initiation of biological agents.
Results: This study included 220 patients, 101 females and 119 males. SIRI was significantly higher in male patients compared to females (P < 0.001). Although not statistically significant, SII and SIRI were higher in obese patients, patients with severe psoriasis, longer disease duration, nail involvement and patients who received previous biological agent treatment. SII was also higher in patients with hypertension, diabetes, hepatic steatosis, depression and coronary artery disease (P = 0.801, P = 0.752, P = 0.706, P = 0.079, P = 0.861, respectively), whereas SIRI was higher in patients with diabetes and depression (P = 0.263, P = 0.777, respectively). Both SII and SIRI statistically significantly decreased after treatment with adalimumab, infliximab, ixekizumab, secukinumab, ustekinumab and risankizumab.
Conclusions: SII and SIRI may indicate the severity of psoriasis as well as SII may be associated with psoriatic arthritis, hypertension, hepatic steatosis and coronary artery disease in patients with psoriasis. There is no consensus on the biomarkers that can be used to create an optimized treatment strategy in psoriasis. Therefore, SII and SIRI may be helpful in making the choice of treatment and in the follow-up of patients with psoriasis treated with biological agents.
References
Sugimoto E, Matsuda H, Shibata S, et al. Impact of pretreatment systemic inflammatory markers on treatment persistence with biologics and conventional systemic therapy: a retrospective study of patients with psoriasis vulgaris and psoriatic arthritis. J Clin Med. 2023;12(8):3046. DOI: 10.3390/jcm12083046. PMID: 37109382. PMCID: PMC10145777.
Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840-848. DOI: 10.1111/bjd.18245. PMID: 31225638. PMCID: PMC7187293.
Tashiro T, Sawada Y. Psoriasis and systemic inflammatory disorders. Int J Mol Sci. 2022;23(8):4457. DOI: 10.3390/ijms23084457. PMID: 35457278. PMCID: PMC9028262.
Wu JJ, Kavanaugh A, Lebwohl MG, Gniadecki R, Merola JF. Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):797-806. DOI: 10.1111/jdv.18044. PMID: 35238067. PMCID: PMC9313585.
Honma M, Nozaki H. Molecular pathogenesis of psoriasis and biomarkers reflecting disease activity. J Clin Med. 2021;10(15):3199. DOI: 10.3390/jcm10153199. PMID: 34361983. PMCID: PMC8346978.
Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up cohort study of 42,875 US adults. J Clin Med. 2023;12(3):1128. DOI: 10.3390/jcm12031128. PMID: 36769776. PMCID: PMC9918056.
Fest J, Ruiter R, Mulder M, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer-a population-based cohort study. Int J Cancer. 2020;146(3):692-698. DOI: 10.1002/ijc.32303. PMID: 30924141. PMCID: PMC6916270.
Song Y, Guo W, Li Z, Guo D, Li Z, Li Y. Systemic immune-inflammation index is associated with hepatic steatosis: evidence from NHANES 2015-2018. Front Immunol. 2022;13:1058779. DOI: 10.3389/fimmu.2022.1058779. PMID: 36466832. PMCID: PMC9718528.
Li X, Huan J, Lin L, Hu Y. Association of systemic inflammatory biomarkers with depression risk: results from national health and nutrition examination survey 2005-2018 analyses. Front Psychiatry. 2023;14:1097196. DOI: 10.3389/fpsyt.2023.1097196. PMID: 36846218. PMCID: PMC9945233.
Yorulmaz A, Hayran Y, Akpinar U, Yalcin B. Systemic immune-inflammation index (SII) predicts increased severity in psoriasis and psoriatic arthritis. Curr Health Sci J. 2020;46(4):352-357. DOI: 10.12865/CHSJ.46.04.05. PMID: 33717509. PMCID: PMC7948012.
Dincer Rota D, Tanacan E. The utility of systemic-immune inflammation index for predicting the disease activation in patients with psoriasis. Int J Clin Pract. 2021;75(6):e14101. DOI: 10.1111/ijcp.14101. PMID: 33619821.
Conforti C, Currado D, Navarini L, et al. Moderate-to-severe plaque psoriasis, described by PASI ≥10%, can be associated with higher cardiovascular risk according to seven risk algorithms: results of a 10-year single-center retrospective study and clinical management of psoriatic patients with cardiovascular risk. Dermatol Ther. 2020;33(6):14451. DOI: 10.1111/dth.14451. PMID: 33098612.
Liu N, Birstler J, Venkatesh M, Hanrahan L, Chen G, Funk L. Obesity and BMI cut points for associated comorbidities: electronic health record study. J Med Internet Res. 2021;23(8):24017. DOI: 10.2196/24017. PMID: 34383661. PMCID: PMC8386370.
He L, Xie X, Xue J, Xie H, Zhang Y. Association of the systemic immune-inflammation index with all-cause mortality in patients with arteriosclerotic cardiovascular disease. Front Cardiovasc Med. 2022;9:952953. DOI: 10.3389/fcvm.2022.952953. PMID: 36172591. PMCID: PMC9510918.
Han K, Shi D, Yang L, et al. Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Ann Med. 2022;54(1):1667-1677. DOI: 10.1080/07853890.2022.2083671. PMID: 35695557. PMCID: PMC9225721.
Melikoglu M, Pala E. Systemic Immune-inflammation index as a biomarker of psoriasis severity. Arch Basic Clin Res. 2023;5(2):291-295. DOI: 10.5152/ABCR.2023.22124.
Ibrahim SH, Guan M, Li S. Systemic immune inflammatory index is associated with pustular psoriasis: a single center retrospective study. J Cosmet Dermatol Sci Appl. 2022;12(4):174-186. DOI: 10.4236/jcdsa.2022.124015.
Kelesoglu Dincer AB, Sezer S. Systemic Immune inflammation index as a reliable disease activity marker in psoriatic arthritis. J Coll Physicians Surg Pak. 2022;32(6):773-778. DOI: 10.29271/jcpsp.2022.06.773. PMID: 35686411.
Ramessur R, Corbett M, Marshall D, et al. Biomarkers of disease progression in people with psoriasis: a scoping review. Br J Dermatol. 2022;187(4):481-493. DOI: 10.1111/bjd.21627.PMID: 35482474. PMCID: PMC9796834.
Molteni RE. Biomarkers in the pathogenesis, diagnosis, and treatment of psoriasis. Psoriasis (Auckl). 2012;2:55-66. DOI: 10.2147/PTT.S24995.
Jiménez C, Bordagaray MJ, Villarroel JL, et al. Biomarkers in oral fluids as diagnostic tool for psoriasis. Life. 2022;12(4):501. DOI: 10.3390/life12040501. PMID: 35454992. PMCID: PMC9027180.
Published
Issue
Section
License
Copyright (c) 2023 Funda Tamer, Yusuf Can Edek, Ahmet Burhan Aksakal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
